MISTIE II Trial: 365-Day Results Demonstrate Improved Outcomes and Cost Benefit

Summary

This article presents results from the Minimally Invasive Surgery Plus tPA for Intracerebral Hemorrhage Evacuation trial [MISTIE; NCT00224770], which showed that catheter-based clot reduction plus tissue plasminogen activator (MIS + tPA) is safe and may reduce long-term disability after intracerebral hemorrhage.

  • Neurology Clinical Trials
  • Interventional Techniques & Devices
  • Ischemia
  • Neurology Clinical Trials
  • Neurology
  • Interventional Techniques & Devices
  • Ischemia
View Full Text
Back to top

Tools

View Full Page PDF
Citation Tools
Email
MISTIE II Trial: 365-Day Results Demonstrate Improved Outcomes and Cost Benefit
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Neurology Clinical Trials
Interventional Techniques & Devices
Ischemia
Neurology Clinical Trials
Neurology
Interventional Techniques & Devices
Ischemia